小干扰RNA
急性呼吸窘迫综合征
医学
急性呼吸窘迫
肺
趋化因子
炎症
重症监护医学
免疫学
药理学
生物
转染
内科学
细胞培养
遗传学
作者
Makhloufi Zoulikha,Qingqing Xiao,George Frimpong Boafo,Marwa A. Sallam,Zhongjian Chen,Wei He
标识
DOI:10.1016/j.apsb.2021.08.009
摘要
The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of several unmet medical needs, including acute lung injury/acute respiratory distress syndrome (ALI/ARDS) wherein siRNA may be implemented to modify the expression of pro-inflammatory cytokines and chemokines at the mRNA level. The properties such as clear anatomy, accessibility, and relatively low enzyme activity make the lung a good target for local siRNA therapy. However, the translation of siRNA is restricted by the inefficient delivery of siRNA therapeutics to the target cells due to the properties of naked siRNA. Thus, this review will focus on the various delivery systems that can be used and the different barriers that need to be surmounted for the development of stable inhalable siRNA formulations for human use before siRNA therapeutics for ALI/ARDS become available in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI